n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with tofacitinib in 1 studies
| Studies (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Trials (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Recent Studies (post-2010) (n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine) | Studies (tofacitinib) | Trials (tofacitinib) | Recent Studies (post-2010) (tofacitinib) |
|---|---|---|---|---|---|
| 214 | 5 | 58 | 1,619 | 214 | 1,519 |
| Protein | Taxonomy | n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine (IC50) | tofacitinib (IC50) |
|---|---|---|---|
| Chain A, Tyrosine-protein kinase | Homo sapiens (human) | 0.0117 | |
| Chain A, Tyrosine-protein kinase | Homo sapiens (human) | 0.0117 | |
| Chain A, Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0117 | |
| Dual specificity mitogen-activated protein kinase kinase 7 | Homo sapiens (human) | 0.0815 | |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.2065 | |
| Rho-associated protein kinase 2 | Homo sapiens (human) | 3.4 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0815 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0815 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 2.6933 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.015 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.0014 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.0037 | |
| Cytochrome P450 2A6 | Homo sapiens (human) | 0.012 | |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | 0.0575 | |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | 0.1411 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.0016 | |
| Tyrosine-protein kinase Tec | Homo sapiens (human) | 0.0815 | |
| Tyrosine-protein kinase TXK | Homo sapiens (human) | 0.0815 | |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | 0.0815 | |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | 0.0815 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0408 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.0006 | |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | 0.0815 | |
| Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | 0.0815 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0815 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.0143 | |
| Tyrosine-protein kinase JAK3 | Mus musculus (house mouse) | 0.664 | |
| Tyrosine-protein kinase JAK2 | Rattus norvegicus (Norway rat) | 3.57 | |
| Tyrosine-protein kinase JAK3 | Rattus norvegicus (Norway rat) | 1.2 | |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | 5.76 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Warren, RB; Yiu, ZZ | 1 |
1 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and tofacitinib
| Article | Year |
|---|---|
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |